Sort
82,697 grants matching “vaccine development”
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity
$685,533James B McLachlan · Tulane University Of Louisiana · R01 · FY2022 · AI
Vervet Research Colony as a Biomedical Resource
$685,530Jay R Kaplan · Wake Forest University Health Sciences · P40 · FY2010 · RR
Occurrence and Outcome of Dual HIV-1 Infection
$685,492James Ivan Mullins · University Of Washington · R37 · FY2011 · AI
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics
$685,484Samuel Lai · Univ Of North Carolina Chapel Hill · R01 · FY2020 · HL
RNA:protein interactions that dictate the success of influenza virus infection
$685,427Andrew Mehle · University Of Wisconsin-Madison · R01 · FY2023 · AI
RNA:protein interactions that dictate the success of influenza virus infection
$685,427Andrew Mehle · University Of Wisconsin-Madison · R01 · FY2022 · AI
Epidemiology of Helicobacter Pylori Transmission
$685,412Julie Parsonnet · Stanford University · R01 · FY2006 · AI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination
$685,339Evan Alexander Scott · Northwestern University · R01 · FY2019 · AI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination
$685,339Evan Alexander Scott · Northwestern University · R01 · FY2020 · AI
Vervet Research Colony as a Biomedical Resource
$685,325Jay R Kaplan · Wake Forest University Health Sciences · P40 · FY2015 · OD
Generating Native Env Glycosylation in HIV Vaccine Candidates
$685,263Heather R Desaire · University Of Kansas Lawrence · R01 · FY2016 · AI
Analytic Methods for HIV Treatment and Co-Factor Effects
$685,244James M Robins · Harvard School Of Public Health · R37 · FY2011 · AI
Development of a Novel, Sensitive ZIKV-Specific Sero-diagnostic Assay Utilizing Biologically Inspired Synthetic Molecules
$685,242Donald S. Burke · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI
Resource Component
$685,235Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2025 · OD
Epitope and mechanistic correlates of broadly protective human antibodies for pneumococcal infection
$685,212Jarrod Mousa · Florida State University · R01 · FY2024 · AI
Human M Cells Require Coronin 1a
$685,191Nicholas Constantine Zachos · Vanderbilt University Medical Center · R01 · FY2025 · AI
Impact of early childhood malaria prevention on malaria risk at school entry (ERASE)
$685,104Miriam K Laufer · University Of Maryland Baltimore · R01 · FY2024 · AI
Modulation of the early host response to SIV in pathogenic infection
$685,093Amitinder Kaur · Harvard Medical School · R01 · FY2012 · AI
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B
$685,089Eric Bruening · Tomegavax, Inc. · R44 · FY2018 · AI
PET Probes Targeting Immune Cells for Imaging Tuberculosis
$685,055Carolyn J Anderson · University Of Pittsburgh At Pittsburgh · R01 · FY2016 · AI
Development of Pre-Erythrocytic Malaria Vaccines
$685,038Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Development Of A Vaccine For Leishmania Major Infection
$685,037Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Dengue-Zika: Correlates of Cross-Protection in Non-Human Primates
$685,020Carlos A Sariol · University Of Puerto Rico Med Sciences · R01 · FY2022 · AI
Cellular and Molecular Mechanisms of Immune Inflammatory
$685,009Johns Hopkins University · T32 · FY2005 · AI
Bronx-Lebanon Hospital Clinical Trials Unit
$685,005Murli U Purswani · Bronxcare Health System · UM1 · FY2012 · AI